See the DrugPatentWatch profile for Xatmep
What is Xatmep?
Xatmep is the brand name used in Japan and Korea for the ready‑to‑inject formulation of abatacept, a biologic that blocks T‑cell co‑stimulation. It contains 125 mg of abatacept in 1.5 mL and is administered subcutaneously or intravenously for rheumatoid arthritis (RA) and other immune‑mediated disorders.[1][2]
Who manufactures Xatmep?
The product is manufactured by AbbVie (Janssen Biotech) and sold under the brand “Xatmo‑P” in those markets. It is part of AbbVie’s portfolio of immune‑modulating therapies.[3]
How does it work?
Abatacept binds to CD80/86 on antigen‑presenting cells, preventing interaction with CD28 on T‑cells. This blockade reduces T‑cell activation and dampens the inflammatory cascade that drives joint damage in RA.[4] The ready‑to‑use formulation simplifies dosing and reduces preparation time compared with the original vial.
What conditions can it treat?
Beyond RA, abatacept is approved for juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), and systemic lupus erythematosus (SLE) in certain regions. In Japan, Xatmep is indicated for moderate‑to‑severe RA in patients who have failed or are intolerant to disease‑modifying antirheumatic drugs (DMARDs).[5]
How is Xatmep administered?
The subcutaneous route involves a single 125 mg injection every four weeks, while the intravenous regimen delivers 125 mg at weeks 0, 2, and 4, then every 4 weeks. The ready‑to‑use vial allows for direct injection without reconstitution, which is especially useful in outpatient settings.[6]
What are the common side effects?
Infections—particularly upper respiratory tract infections, nasopharyngitis, and pneumonia—are the most frequent adverse events. Other reported effects include headache, arthralgia, and mild infusion reactions for IV dosing. Rare but serious risks involve reactivation of latent tuberculosis and hypersensitivity reactions.[7]
Is Xatmep covered by insurance?
In Japan, the National Health Insurance System covers Xatmep for approved indications, provided patients meet criteria such as inadequate response to conventional DMARDs. In Korea, coverage is similar, but patients may need prior authorization. Internationally, coverage varies by country and insurer.[8]
When is Xatmep available worldwide?
Xatmep (Xatmo‑P) has been marketed in Japan since 2016 and in Korea since 2019. It is not yet approved in the U.S. or EU; however, the generic abatacept is available under different brand names in those markets.[9]
What alternatives exist?
Other biologics targeting T‑cell co‑stimulation or cytokines include abatacept’s biosimilar “Abatacept‑s” and different mechanisms such as TNF inhibitors (adalimumab, etanercept), IL‑6 inhibitors (tocilizumab), and JAK inhibitors (tofacitinib). Choice depends on disease severity, patient comorbidities, and prior therapy history.[10]
What are the pricing considerations?